{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T01:24:14Z","timestamp":1781832254473,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T00:00:00Z","timestamp":1709164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim Pharma GmbH und Co. KG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.ejca.2024.113926","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T05:37:42Z","timestamp":1707975462000},"page":"113926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer \u2013 Results of a phase 1b clinical trial"],"prefix":"10.1016","volume":"201","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6048-4711","authenticated-orcid":false,"given":"Danmei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Benedikt Westphalen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Quante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk T.","family":"Waldschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1344-9056","authenticated-orcid":false,"given":"Swantje","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"K\u00fctting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klara","family":"Dorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3580-2313","authenticated-orcid":false,"given":"Kathrin","family":"Heinrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Boukovala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Boeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-3321","authenticated-orcid":false,"given":"Volker","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejca.2024.113926_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"18","key":"10.1016\/j.ejca.2024.113926_bib2","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"25","key":"10.1016\/j.ejca.2024.113926_bib3","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.ejca.2024.113926_bib4","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ccr.2012.07.024","article-title":"EGF receptor is required for KRAS-induced pancreatic tumorigenesis","volume":"22","author":"Ardito","year":"2012","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ejca.2024.113926_bib5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ccr.2012.08.001","article-title":"EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma","volume":"22","author":"Navas","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.ejca.2024.113926_bib6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.3390\/cancers3021513","article-title":"Epidermal Growth Factor Receptor in Pancreatic Cancer","volume":"3","author":"Oliveira-Cunha","year":"2011","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.ejca.2024.113926_bib7","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada clinical trials group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113926_bib8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejca.2018.02.008","article-title":"Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospective phase II study of the \u2018Arbeitsgemeinschaft Internistische Onkologie","volume":"94","author":"Haas","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113926_bib9","unstructured":"FDA. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021743s14s16lbl.pdf\u3009. Accessed April 17, 2023. www.fda.gov\/medwatch."},{"key":"10.1016\/j.ejca.2024.113926_bib10","unstructured":"FDA. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/201292s014lbl.pdf\u3009. Accessed April 17, 2023. www.fda.gov\/medwatch."},{"key":"10.1016\/j.ejca.2024.113926_bib11","unstructured":"Kristina Gregory N., Miranda Hughes O., Aisner D.L., et al. NCCN Guidelines Version 3.2023 Non-Small Cell Lung Cancer Continue NCCN Guidelines Panel Disclosures. Published online 2023. Accessed April 17, 2023. \u3008https:\/\/www.nccn.org\/home\/member-\u3009."},{"issue":"3","key":"10.1016\/j.ejca.2024.113926_bib12","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11523-015-0403-8","article-title":"Afatinib, an Irreversible EGFR Family Inhibitor, Shows Activity Toward Pancreatic Cancer Cells, Alone and in Combination with Radiotherapy, Independent of KRAS Status","volume":"11","author":"Huguet","year":"2016","journal-title":"Target Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2024.113926_bib13","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.2174\/1871520620666200508090515","article-title":"The Anti-Tumor Activity of Afatinib in Pancreatic Ductal Adenocarcinoma Cells","volume":"20","author":"Ye","year":"2020","journal-title":"Anticancer Agents Med Chem"},{"issue":"10","key":"10.1016\/j.ejca.2024.113926_bib14","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1038\/bjc.2011.396","article-title":"Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells","volume":"105","author":"Ioannou","year":"2011","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.ejca.2024.113926_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejca.2020.12.029","volume":"146","author":"Haas","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113926_bib16","unstructured":"RECIST 1.1 \u2013 RECIST. Accessed April 18, 2023. \u3008https:\/\/recist.eortc.org\/recist-1-1-2\/\u3009."},{"key":"10.1016\/j.ejca.2024.113926_bib17","unstructured":"Cancer Institute N. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Published online 2009. Accessed April 18, 2023. \u3008http:\/\/www.meddramsso.com\u3009."},{"issue":"10","key":"10.1016\/j.ejca.2024.113926_bib18","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose Escalation Methods in Phase I Cancer Clinical Trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"JNCI Journal of the National Cancer Institute"},{"issue":"1","key":"10.1016\/j.ejca.2024.113926_bib19","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-020-6636-7","article-title":"Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study","volume":"20","author":"Westphalen","year":"2020","journal-title":"BMC Cancer"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924001023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:44:15Z","timestamp":1760733855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924001023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":19,"alternative-id":["S0959804924001023"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113926","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer \u2013 Results of a phase 1b clinical trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113926","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113926"}}